Subscribe to RSS
Effect of the Extent of Resection on Survival Outcome in Glioblastoma: Propensity Score Approach
Objective To evaluate the effectiveness of the extent of resection (EOR) on survival outcome using propensity score-based approaches.
Materials and Methods A retrospective cohort study was performed in patients with newly diagnosed glioblastoma. Propensity score matching (PSM) and propensity score regression adjustment were used in the matched and unmatched dataset, respectively. Therefore, the Kaplan-Meier survival curve and Cox's regression analyses were performed to determine the effect of the EOR on survival outcomes.
Results One hundred and sixty-eight patients were included for analyzes. The total tumor resection in the unmatched dataset was 22.6% of all cases. Using PSM, incomplete tumor resection had an unfavorable survival outcome when compared with total tumor resection (hazard ratio (HR) 2.92, 95% confidence interval [CI] 1.72–4.94). Additionally, biopsy and partial tumor resection were significantly associated with poor prognosis when compared with total tumor resection using propensity score regression adjustment (HR of biopsy 1.89, 95%CI 1.13–3.16 and HR of partial resection 1.89, 95%CI 1.28–2.80).
Conclusions Patients with total tumor resection tend to have a more favorable prognosis than patients with partial tumor resection. The propensity score-based analysis is an alternative approach to evaluate the effect of an intervention that has limitations to perform a randomized controlled trial.
Conception and design: T. T.
Administrative support: T. T., S. M.
Provision of study materials or patients: T. T., S. M.
Collection and assembly of data: T. T., S. M.
Data analysis and interpretation: T. T.
Manuscript writing: All authors
Final approval of manuscript: All authors
Received: 20 April 2020
Accepted: 05 August 2020
16 October 2020 (online)
© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Revinter Publicações Ltda
Rio de Janeiro, Brazil
- 1 Lacroix M, Abi-Said D, Fourney DR. et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95 (02) 190-198
- 2 Tunthanathip T, Ratanalert S, Sae-Heng S, Oearsakul T. Butterfly Tumor of the Corpus Callosum: Clinical Characteristics, Diagnosis, and Survival Analysis. J Neurosci Rural Pract 2017; 8 (Suppl. 01) S57-S65
- 3 Trifiletti DM, Alonso C, Grover S, Fadul CE, Sheehan JP, Showalter TN. Prognostic Implications of Extent of Resection in Glioblastoma: Analysis from a Large Database. World Neurosurg 2017; 103: 330-340
- 4 Chaichana KL, Jusue-Torres I, Navarro-Ramirez R. et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncol 2014; 16 (01) 113-122
- 5 Sanai N, Mirzadeh Z, Polley M-Y. et al. The value of glioblastoma extent of resection: a volumetric analysis of 500 patients. J Neurosurg 2010; 113: A433
- 6 Brown TJ, Brennan MC, Li M. et al. Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. JAMA Oncol 2016; 2 (11) 1460-1469
- 7 Osorio JA, Aghi MK. Optimizing glioblastoma resection: intraoperative mapping and beyond. CNS Oncol 2014; 3 (05) 359-366
- 8 Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T. Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol 2001; 52 (02) 161-171
- 9 Tunthanathip T, Madteng S. Factors associated with the extent of resection of glioblastoma. Precis Cancer Med 2020 http://dx.doi.org/10.21037/pcm.2020.01.01
- 10 Newgard CD, Hedges JR, Arthur M, Mullins RJ. Advanced statistics: the propensity score--a method for estimating treatment effect in observational research. Acad Emerg Med 2004; 11 (09) 953-961
- 11 Tanprasertkul C, Patumanond J, Manusook S. et al. Recurrence of Endometrioma Following Conservative Ovarian Endometrioma Cystectomy: Laparoscopy versus Laparotomy. J Med Assoc Thai 2015; 98 (98) (Suppl. 03) S96-S100
- 12 Agrawal D, Raghavendran K, Schaubel DE, Mishra MC, Rajajee V. A Propensity Score Analysis of the Impact of Invasive Intracranial Pressure Monitoring on Outcomes after Severe Traumatic Brain Injury. J Neurotrauma 2016; 33 (09) 853-858 DOI: 10.1089/neu.2015.4015.
- 13 Cepeda S, Castaño-León AM, Munarriz PM. et al. Effect of decompressive craniectomy in the postoperative expansion of traumatic intracerebral hemorrhage: a propensity score-based analysis. J Neurosurg 2019; 26: 1-13 DOI: 10.3171/2019.2.JNS182025.
- 14 Tunthanathip T, Sangkhathat S, Tanvejsilp P, Kanjanapradit K. Impact of IDH1 Mutation and MGMT Promoter Methylation in Patients with Glioblastoma. [dissertation]. Songkhla: Prince of Songkla University; 2020
- 15 Vecht CJ, Avezaat CJJ, van Putten WL, Eijkenboom WM, Stefanko SZ. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry 1990; 53 (06) 466-471
- 16 Bloch O, Han SJ, Cha S. et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg 2012; 117 (06) 1032-1038
- 17 Ahmadipour Y, Kaur M, Pierscianek D. et al. Association of Surgical Resection, Disability, and Survival in Patients with Glioblastoma. J Neurol Surg A Cent Eur Neurosurg 2019; 80 (04) 262-268
- 18 Hsieh FY. Comparing sample size formulae for trials with unbalanced allocation using the logrank test. Stat Med 1992; 11 (08) 1091-1098 DOI: 10.1002/sim.4780110810.
- 19 Ho D, Imai K, King G. et al. Package ‘MatchIt’. https://cran.r-project.org/web/packages/MatchIt/MatchIt.pdf/ 2018 Accessed 13 March 2019.
- 20 Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res 2011; 46 (03) 399-424
- 21 Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7 (05) 392-401
- 22 Stummer W, Reulen HJ, Meinel T. ALA-Glioma Study Group. et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008; 62 (03) 564-576 , discussion 564–576
- 23 Slof J, Díez Valle R, Galván J. Cost-effectiveness of 5-aminolevulinic acid-induced fluorescence in malignant glioma surgery. Neurologia 2015; 30 (03) 163-168 DOI: 10.1016/j.nrl.2013.11.002.
- 24 Tunthanathip T, Kanjanapradit K. Glioblastoma Multiforme Associated with Arteriovenous Malformation: A Case Report and Literature Review. Ann Indian Acad Neurol 2020; 23 (01) 103-106
- 25 Liu Q, Liu Y, Li W. et al. Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. Acta Neuropathol 2015; 130 (04) 587-597
- 26 Thomas RP, Xu LW, Lober RM, Li G, Nagpal S. The incidence and significance of multiple lesions in glioblastoma. J Neurooncol 2013; 112 (01) 91-97
- 27 Tunthanathip T, Sangkhathat S, Tanvejsilp P, Kanjanapradit K. The clinical characteristics and prognostic factors of multiple lesions in glioblastomas. Clin Neurol Neurosurg 2020; 195: 105891
- 28 Streiner DL, Norman GR. The pros and cons of propensity scores. Chest 2012; 142 (06) 1380-1382
- 29 Tunthanathip T, Sangkhathat S. Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching. Clin Neurol Neurosurg 2020; 191: 105712 DOI: 10.1016/j.clineuro.2020.105712.
- 30 Cottone F, Anota A, Bonnetain F, Collins GS, Efficace F. Propensity score methods and regression adjustment for analysis of nonrandomized studies with health-related quality of life outcomes. Pharmacoepidemiol Drug Saf 2019; 28 (05) 690-699 DOI: 10.1002/pds.4756.